Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Other Operating Expenses (2024 - 2025)

Stoke Therapeutics has reported Other Operating Expenses over the past 2 years, most recently at $152.4 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $152.4 million for Q4 2025, up 201.36% from a year ago — trailing twelve months through Dec 2025 was $58.5 million (up 138.9% YoY), and the annual figure for FY2024 was -$150.3 million, changed.
  • Other Operating Expenses for Q4 2025 was $152.4 million at Stoke Therapeutics, up from -$44.9 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for STOK hit a ceiling of $152.4 million in Q4 2025 and a floor of -$150.3 million in Q4 2024.